Approfondimenti generali
ESMO Clinical Practice Guidelines – Waldenstrom’s Macroglobulinaemia [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Dimopoulous MA, et al. Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenström macroglobulinemia EHA 2020; Abstract EP1180 [Apri]
Tam CS, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 Sep 12;134(11):851-859. [Apri]